{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:51:20Z","timestamp":1792623080383,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0351"],"award-info":[{"award-number":["HT9425-23-1-0351"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer is characterized by aggressive metastasis, chemoresistance, and poor survival outcomes. Gaps in understanding of factors that drive these phenotypes have hindered the development of actionable therapeutic targets. We demonstrate that Zinc Finger Protein 217 (ZNF217) is a key pro-metastatic factor in ovarian cancer cells. ZNF217 overexpression dramatically increases proliferation, metastasis, and chemoresistance while its depletion impairs these phenotypes. Consistently, ZNF217 overexpression is associated with poor prognosis in both mouse models and ovarian cancer patients. Interestingly, ZNF217 induces metastatic phenotypes in fallopian tube cells, suggesting potential role in the transition of early-stage tumors to aggressive carcinoma. ZNF217\u2019s oncogenic activity is dependent on its ability to bind DNA and alter multiple processes, including EMT, that are critical in driving different aspects of cancer progression. Thus, our data establishes ZNF217 as a potent oncogene in ovarian cancer cells that impacts multiple steps in the metastatic process and a potential therapeutic target.<\/jats:p>","DOI":"10.1038\/s41698-025-01153-8","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:21:00Z","timestamp":1764847260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ZNF217 promotes ovarian cancer progression by impacting multiple pivotal steps in the metastatic process"],"prefix":"10.1038","volume":"9","author":[{"given":"Kathryn C.","family":"Wardrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha J.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Navarathna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan E.","family":"Tulapurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achuth","family":"Padmanabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1153_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1153_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart, C., Ralyea, C. & Lockwood, S. Ovarian cancer: an integrated review. Semin. Oncol. Nurs. 35, 151\u2013156 (2019).","journal-title":"Semin. Oncol. Nurs."},{"key":"1153_CR3","doi-asserted-by":"publisher","first-page":"41566","DOI":"10.18632\/oncotarget.5893","volume":"6","author":"PA Cohen","year":"2015","unstructured":"Cohen, P. A., Donini, C. F., Nguyen, N. T., Lincet, H. & Vendrell, J. A. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget 6, 41566\u201341581 (2015).","journal-title":"Oncotarget"},{"key":"1153_CR4","doi-asserted-by":"publisher","first-page":"e14632","DOI":"10.1371\/journal.pone.0014632","volume":"6","author":"Y Tabach","year":"2011","unstructured":"Tabach, Y. et al. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One 6, e14632 (2011).","journal-title":"PLoS One"},{"key":"1153_CR5","first-page":"3378","volume":"11","author":"Y Li","year":"2021","unstructured":"Li, Y., Wu, H., Wang, Q. & Xu, S. ZNF217: the cerberus who fails to guard the gateway to lethal malignancy. Am. J. Cancer Res. 11, 3378\u20133405 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"1153_CR6","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1038\/onc.2010.289","volume":"29","author":"SR Krig","year":"2010","unstructured":"Krig, S. R. et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene 29, 5500\u20135510 (2010).","journal-title":"Oncogene"},{"key":"1153_CR7","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1172\/JCI129249","volume":"130","author":"JJ Northey","year":"2020","unstructured":"Northey, J. J. et al. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. J. Clin. Invest 130, 5721\u20135737 (2020).","journal-title":"J. Clin. Invest"},{"key":"1153_CR8","doi-asserted-by":"publisher","first-page":"84893","DOI":"10.18632\/oncotarget.12753","volume":"7","author":"X Jiang","year":"2016","unstructured":"Jiang, X. et al. Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress. Oncotarget 7, 84893\u201384906 (2016).","journal-title":"Oncotarget"},{"key":"1153_CR9","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/0008-5472.CAN-21-0356","volume":"81","author":"M Kodama","year":"2021","unstructured":"Kodama, M. et al. Sleeping beauty transposon mutagenesis identifies genes driving the initiation and metastasis of uterine leiomyosarcoma. Cancer Res. 81, 5413\u20135424 (2021).","journal-title":"Cancer Res."},{"key":"1153_CR10","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1002\/cncr.26598","volume":"118","author":"MT Rahman","year":"2012","unstructured":"Rahman, M. T. et al. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 118, 2846\u20132857 (2012).","journal-title":"Cancer"},{"key":"1153_CR11","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.humpath.2014.07.020","volume":"45","author":"HN Huang","year":"2014","unstructured":"Huang, H. N. et al. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Hum. Pathol. 45, 2318\u20132325 (2014).","journal-title":"Hum. Pathol."},{"key":"1153_CR12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/labinvest.2011.56","volume":"91","author":"XG Mao","year":"2011","unstructured":"Mao, X. G. et al. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest. 91, 1068\u20131078 (2011).","journal-title":"Lab Invest."},{"key":"1153_CR13","first-page":"3091","volume":"32","author":"MT Rahman","year":"2012","unstructured":"Rahman, M. T. et al. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma. Anticancer Res. 32, 3091\u20133095 (2012).","journal-title":"Anticancer Res."},{"key":"1153_CR14","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb.) 5, 100625 (2024).","journal-title":"Innovation (Camb.)"},{"key":"1153_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy, B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br. J. Pharm. 181, 362\u2013374 (2024).","journal-title":"Br. J. Pharm."},{"key":"1153_CR16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064 (2010).","journal-title":"Am. J. Pathol."},{"key":"1153_CR17","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2019","unstructured":"Motohara, T. et al. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 38, 2885\u20132898 (2019).","journal-title":"Oncogene"},{"key":"1153_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep26191","volume":"6","author":"AJ Cole","year":"2016","unstructured":"Cole, A. J. et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci. Rep. 6, 26191 (2016).","journal-title":"Sci. Rep."},{"key":"1153_CR19","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","volume":"26","author":"WA Freed-Pastor","year":"2012","unstructured":"Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268\u20131286 (2012).","journal-title":"Genes Dev."},{"key":"1153_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","volume":"5","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Cao, L., Nguyen, D. & Lu, H. TP53 mutations in epithelial ovarian cancer. Transl. Cancer Res. 5, 650\u2013663 (2016).","journal-title":"Transl. Cancer Res."},{"key":"1153_CR21","doi-asserted-by":"publisher","first-page":"38190","DOI":"10.1074\/jbc.M111.301234","volume":"286","author":"N Nunez","year":"2011","unstructured":"Nunez, N. et al. The multi-zinc finger protein ZNF217 contacts DNA through a two-finger domain. J. Biol. Chem. 286, 38190\u201338201 (2011).","journal-title":"J. Biol. Chem."},{"key":"1153_CR22","doi-asserted-by":"publisher","first-page":"9703","DOI":"10.1074\/jbc.M611752200","volume":"282","author":"SR Krig","year":"2007","unstructured":"Krig, S. R. et al. Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J. Biol. Chem. 282, 9703\u20139712 (2007).","journal-title":"J. Biol. Chem."},{"key":"1153_CR23","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1038\/sj.onc.1210126","volume":"26","author":"JJ Cowger","year":"2007","unstructured":"Cowger, J. J., Zhao, Q., Isovic, M. & Torchia, J. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 26, 3378\u20133386 (2007).","journal-title":"Oncogene"},{"key":"1153_CR24","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41375-023-02013-9","volume":"37","author":"F Briest","year":"2023","unstructured":"Briest, F. et al. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma. Leukemia 37, 2237\u20132249 (2023).","journal-title":"Leukemia"},{"key":"1153_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4161\/epi.4.2.7953","volume":"4","author":"MS Banck","year":"2009","unstructured":"Banck, M. S. et al. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics 4, 100\u2013106 (2009).","journal-title":"Epigenetics"},{"key":"1153_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-520","volume":"15","author":"S Frietze","year":"2014","unstructured":"Frietze, S. et al. Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha. BMC Genom. 15, 520 (2014).","journal-title":"BMC Genom."},{"key":"1153_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161\u2013169 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"1153_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26\u201335 (2007).","journal-title":"J. Pathol."},{"key":"1153_CR29","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","volume":"26","author":"K Levanon","year":"2008","unstructured":"Levanon, K., Crum, C. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284\u20135293 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1153_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros, F. et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230\u2013236 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"1153_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","volume":"191","author":"IM Shih","year":"2021","unstructured":"Shih, I. M., Wang, Y. & Wang, T. L. The origin of ovarian cancer species and precancerous landscape. Am. J. Pathol. 191, 26\u201339 (2021).","journal-title":"Am. J. Pathol."},{"key":"1153_CR32","first-page":"3038","volume":"7","author":"J Li","year":"2014","unstructured":"Li, J., Song, L., Qiu, Y., Yin, A. & Zhong, M. ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer. Int. J. Clin. Exp. Pathol. 7, 3038\u20133047 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1153_CR33","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1096\/fj.14-266718","volume":"29","author":"F Ye","year":"2015","unstructured":"Ye, F., Chen, C., Qin, J., Liu, J. & Zheng, C. Genetic profiling reveals an alarming rate of cross-contamination among human cell lines used in China. FASEB J. 29, 4268\u20134272 (2015).","journal-title":"FASEB J."},{"key":"1153_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3892\/ijo.2014.2747","volume":"46","author":"P Brachova","year":"2015","unstructured":"Brachova, P. et al. TP53 oncomorphic mutations predict resistance to platinum and taxane based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J. Oncol. 46, 607\u2013618 (2015).","journal-title":"Int J. Oncol."},{"key":"1153_CR35","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1128\/MCB.00246-08","volume":"28","author":"G Thillainadesan","year":"2008","unstructured":"Thillainadesan, G. et al. Genome analysis identifies the p15ink4b tumor suppressor as a direct target of the ZNF217\/CoREST complex. Mol. Cell Biol. 28, 6066\u20136077 (2008).","journal-title":"Mol. Cell Biol."},{"key":"1153_CR36","doi-asserted-by":"publisher","first-page":"e0232565","DOI":"10.1371\/journal.pone.0232565","volume":"15","author":"A Suarez-Arnedo","year":"2020","unstructured":"Suarez-Arnedo, A. et al. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS One 15, e0232565 (2020).","journal-title":"PLoS One"},{"key":"1153_CR37","doi-asserted-by":"publisher","unstructured":"Foty, R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J. Vis. Exp. https:\/\/doi.org\/10.3791\/2720 (2011).","DOI":"10.3791\/2720"},{"key":"1153_CR38","doi-asserted-by":"publisher","first-page":"e0294236","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang, D. et al. SRplot: A free online platform for data visualization and graphing. PLoS One 18, e0294236 (2023).","journal-title":"PLoS One"},{"key":"1153_CR39","doi-asserted-by":"publisher","unstructured":"Cordero, A. B., Kwon, Y., Hua, X. & Godwin, A. K. In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J. Vis. Exp. https:\/\/doi.org\/10.3791\/2125 (2010).","DOI":"10.3791\/2125"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01153-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:21:01Z","timestamp":1764847261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01153-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01153-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}